EC Number   |
Expression |
Reference |
|---|
   2.4.1.150 | down |
GCNT3 downregulation by shGCNT3 7, of several shRNAs targeting GCNT3 shGCNT3s, shGCNT3 7 has the best inhibitory capacity (protein and mRNA) |
760171 |
| 2.4.1.150 | down |
in mouse pancreatic cancer tumors, GCNT3 upregulation (103fold) is correlated with increased expression of mucins (5 to 87fold). Pancreata from 6-week-old Kras mice treated with talniflumate for 1 week show a significant decrease in GCNT3 and mucin expression in PanIN lesions. Further, GCNT3 protein expression is significantly decreased in the pancreas of talniflumate-treated Kras mice compared with untreated control mouse pancreas. mRNA expression of GCNT3 is also observed to be lower in pancreatic tissues from talniflumate-treated mice |
-, 758993 |
| 2.4.1.150 | down |
talniflumate alone and in combination with low-dose gefitinib reduces GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro, in silico molecular docking studies. Talniflumate binds to GCNT3 with a docking affinity of -8.3 kcal/mol and deeper in the pocket of GCNT3. GALB1,3GALNAC's best docking affinity is -7.51 kcal/mol, achieved closer to the surface of GCNT3 |
758993 |
| 2.4.1.150 | up |
modulation of GCNT3 expression in the presence of 5-fluorouracil (5FU) at 0.03 mM, a robust induction of GCNT3 expression is observed in SW family of non-resistant cells with a statistically significant 3.76fold increase in SW620 metastatic cells, while no such induction is observed in SW5FU cells or in HT-29 cell line, which has the highest levels of endogenous GCNT3 |
760171 |
